Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).

  • FEAnalytics.com
  • FEInvest.net
  • FETransmission.com
  • Investegate.co.uk
  • Trustnet.hk
  • Trustnetoffshore.com
  • Trustnetmiddleeast.com

For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.

WHAT INFORMATION DO WE COLLECT ABOUT YOU?

We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.

COOKIES

In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.

HOW WE USE INFORMATION

We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.

ACCESS TO YOUR INFORMATION AND CORRECTION

We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.

WHERE WE STORE YOUR PERSONAL DATA

The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.

CHANGES TO OUR PRIVACY POLICY

Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.

OTHER WEBSITES

Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.

CONTACT

If you want more information or have any questions or comments relating to our privacy policy please email publishing@financialexpress.net in the first instance.

 Information  X 
Enter a valid email address

Intnl. Biotechnology (IBT)

  Print      Mail a friend

Friday 21 April, 2017

Intnl. Biotechnology

Half-year Report

RNS Number : 9188C
Intl. Biotechnology Trust PLC
21 April 2017
 

INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)

Half Yearly Report for the six months ended 28 February 2017

 

This announcement contains regulated information.

 

 

Chairman's Statement

Summary

In the six months to 28 February 2017, the Net Asset Value (NAV) per Ordinary share of the Company rose from 575.1p to 656.7p, including a currency gain of £11.6m, equivalent to 30.9p per share. The NAV per share returned 16.2% including the first dividend payment of 11.5p per share, which was announced in December 2016. Over the same period, the Ordinary share price of the Company increased by 21.1%. This compares to a rise in the NASDAQ Biotechnology Index (NBI) of 12.2% and a gain in the FTSE All-Share Index of 8.6%. All figures are on a total return basis and are sterling-adjusted.  The quoted portfolio has performed very strongly, outperforming the benchmark combined with a 0.5% hurdle by 9.6% as at 28 February 2017.

 

After a period of volatility for biotechnology stocks, many of the uncertainties surrounding the US political environment and drug pricing have been resolved, resulting in a return to growth for the sector. The outlook is more fully explained in the Investment Manager's Report.

 

Longer-term results

The Company's performance since our lead investment manager, Carl Harald Janson, joined the SVLS team in September 2013 has been very impressive. Over the last three years, the Company has significantly outperformed the NBI on both a NAV and share price basis, with an outperformance of 22.3% and 29.3% respectively.  Shareholders will also be pleased by our very substantial outperformance of the broader UK equity market, as measured by the FTSE All-Share Index. Over the last three years, our NAV is up by 75.2%, versus a return of 20.2% from the UK market as a whole.

 

Unquoted portfolio

Following the approval of Shareholders granted at the general meeting held on 29 September 2016, allowing us to invest directly into unquoted, including venture, funds, we made a commitment of $30.0m into SV Life Sciences Fund VI (SV Fund VI), of which $9.3m (£7.5m) was invested at the outset. Investing directly into the venture fund allows us a broad diversified access to a wider range of unquoted investments. Our investment in SV Fund VI will increase slowly over the investment period and overlap with the exits of our existing unquoted companies. The Board expects the unquoted portfolio to remain within the guideline range of 10-15% of total investments.

 

Dividends, buybacks and discount

I am pleased to report that our first dividend payment was made to our Shareholders on 31 January 2017 at a rate of 11.5p per share. The dividend will be 4% of NAV as at 31 August 2016, paid in two equal tranches in January and August. As anticipated, the underlying growth of our investments is more than sufficient to support the payment of the dividend out of capital growth.

 

The Company bought back 125,000 shares at a cost of £0.6m during this six month period, as part of discount management for the benefit of Shareholders. This enhanced the NAV per share by 0.3p because the shares were bought at a discount to NAV that averaged approximately 13.9%.

 

Since the announcement of our policy changes and the introduction of the dividend in September 2016, no further buybacks have been required to maintain our discount control policy. Indeed, the discount narrowed to 10.2% from 13.5% at the previous year end. It is the Board's long-term intention to continue to reduce the discount and its volatility as market conditions allow.

 

Performance fee

As noted above, the exceptional outperformance versus the benchmark has given rise to a current performance fee accrual of £1.9m. The final position of any performance fee will be determined at the year end, 31 August 2017.

 

Prospects

The Investment Manager has successfully outperformed the market in varying conditions, in both rising and falling markets. Drug pricing and political concerns have prevented the sector from participating in the broader market rally which I believe gives investors an excellent opportunity to gain exposure to a sector with exciting growth prospects. It is clear that the larger names within the biotechnology sector are seeing their growth rates slow. The Investment Manager has taken action by tilting the Company away from these names and into the higher growth mid-sized companies by investing in the next generation of businesses with newly launched drugs and innovative pipelines. I am optimistic that exposure to the sector through a fund managed by medical experts can identify such names and generate returns for our Shareholders.

 

Alan Clifton

Chairman

20 April 2017

 

Investment Manager's Review

Summary

In the six months ended 28 February 2017, the Company's NAV per share rose by 16.2% including the dividend. The NBI increased by 12.2%, and the FTSE All-Share Index rose by 8.6%. All figures are on a total return basis and are sterling-adjusted.

 

By subsector, 80% of the portfolio was invested in therapeutics, 10% in specialty pharmaceuticals, 4% in life science tools, diagnostics and services, 4% in medical devices and 3% in a venture capital fund, SV Fund VI. SV Fund VI makes investments into unquoted companies across three sectors; biotechnology (40%), healthcare services and IT (40%) and medical devices (20%). Cash and other net assets were -1% of NAV.

 

Quoted and Unquoted performance

At 28 February 2017, for financial reporting the quoted portfolio represented 90.4% of NAV at £224.6m. The unquoted portfolio represented 9.6% of NAV at £23.7m. Companies that were first invested in from the unquoted pool and have now become quoted but continue to be managed by the unquoted investment managers are included within the unquoted portfolio for the purposes of performance measurement. Based on the classification of the investments as adjusted for performance measurement, the quoted portfolio was 87.7% of the portfolio, whilst the unquoted portfolio represented 12.3%. 

 

Quoted Portfolio

The return on the quoted portfolio was 23.2%, which outperformed the benchmark index, the NBI, by 9.9% compared on a geometric basis with the NBI total return of 12.2%. On an arithmetic basis, the quoted portfolio outperformed the NBI by 11.0%. The relative geometric performance is used for the purpose of calculating the performance fee.

 

Three portfolio holdings were the subjects of successful bids during the period under review, Ariad, Actelion and CoLucid.

 

The largest contributor to performance was Ariad Pharmaceuticals which was acquired by Takeda on 9 January for $24 per share, a 75% premium to the share price at the close of the previous day. Ariad had been identified as a potential M&A target and the Company held a 3.6% position, resulting in a gain of £6.5m on our holding.

 

Eli Lilly announced the acquisition of a portfolio company CoLucid for $960m in an all cash transaction. CoLucid is a neurology company that had a late-stage acute migraine drug in development and Eli Lilly paid a 30% premium to the previous closing share price.

 

Actelion, a Swiss biotechnology company and a long-term holding of the Company, was acquired by Johnson and Johnson for $30bn, a major acquisition which was announced in late January.

 

The Company had a significant position in Tesaro whose drug niraparib was approved by the FDA on 27 March 2017. Niraparib is a PARP inhibitor which is a potential new treatment for ovarian cancer.  Due to the exciting data that has been generated in late stage trials, Tesaro has been in discussions with acquirers. News of the bid speculation helped boost the share price and the Investment Manager chose to lock in profits at that point in time.

 

Another oncology company, Exelixis is in the launch phase of its kidney cancer drug Cabometyx. The launch has been stronger than expected, beating analyst estimates. As with Tesaro, the Investment Manager chose to take profits towards the end of the period to lock in the gains.

 

Incyte, a biopharmaceutical company specialising in oncology product development, increased by £6.2m after upping the guidance on sales of its lead product, Jakafi, and M&A speculation.

 

Genmab, a Danish company that has been a long-term holding of the Company, contributed to performance with the strong launch of their lead asset Darzalex for multiple myeloma (partnered with Johnson and Johnson).

 

FX gains also added to the value of quoted portfolio, with a gain of £11.0m, or 29.3p per share in the period.

 

Unquoted Portfolio

The return for the unquoted portfolio over the six months ended 28 February 2017 was a fall of £4.7m or 16.1%. The combined effect of gains and losses on the unquoted investments was to decrease the NAV by 12.5p per share. This is due to several factors which are explained below. The previous unquoted investments experience higher volatility, as larger investments are made in fewer companies. Our change in the strategy of investing through a more diversified venture capital fund is designed to reduce the volatility of the unquoted portfolio in future periods.

 

As at 28 February 2017, the Company held investments in nine unquoted portfolio companies, one investment in a venture fund, SV Fund VI, and interests in five further companies that have been sold, but where there are further receipts dependent on reaching drug development or financial milestones set at the point when those companies were sold. The Company also holds investments in three previously unquoted companies that are now listed, but which, as described above, are still reported for performance purposes within the unquoted portfolio.

 

Summary of unquoted investments

 

Number of investments

Fair value at 28 Feb 2017 (£'m)

Percentage of NAV

Unquoted

9

11.6

4.7%

Exited with contingent milestones

5

4.6

1.9%

SV Fund VI

14*

7.5

3.0%

Total unquoted

28

23.7

9.6%

Previously unquoted, now listed

3

6.6

2.7%

Total unquoted for performance measurement

31

30.3

12.3%

*The number of investments listed within SV Fund VI represents the number of investments into underlying individual portfolio companies.

 

Following the approval of the change to the investment policy at the general meeting on 29 September 2016, a new investment was made into SV Fund VI. The draw down on the commitment of $30.0m to date is £7.5m ($9.3m), with further amounts due to be drawn down over the investment period. SV Fund VI's investee companies continue to be diversified between biotechnology, healthcare services & IT and medical devices similar to our existing unquoted investments, but with smaller allocations to each individual company, allowing for greater diversification.

 

Kalvista Pharmaceuticals completed a reverse merger in the period into Carbalyn Therapeutics on 23 November and is now listed on the NASDAQ Stock Market. The valuation of Kalvista fell by £0.9m following the listing whilst the company establishes itself. For performance measurement purposes, it remains in the unquoted portfolio, as do Entellus and Transenterix.

 

Entellus completed a secondary equity offering in January 2017 and we sold 15.3% of our holding in the secondary listing for £0.8m. Following the secondary offering, the earnings missed analyst expectations and the share price fell, decreasing our valuation by £1.2m at the period end. We believe the fundamentals of the company remain strong with commercial activities ramping up.

 

In January 2017, Merck notified us that they would be discontinuing development of the assets acquired with OncoEthix due to toxicity concerns. The contingent milestones relating to this investment were written off in full, with an impact on the NAV of £1.2m. Although no further proceeds will be received relating to this investment, the overall return was a multiple of 2.4x.

 

EBR Systems was written down by £1.2m in February based on the latest financing term sheet.  A significant financing round is required to finance the clinical trial for the wireless heart pacemaker which is resulting in earlier investments being down valued.

 

Atopix was sold to Chiesi Farmaceuticals in November 2016, and we received upfront proceeds of £0.5m. Contingent milestones relating to the commercialisation of the CRTH2 antagonist are currently valued at £0.6m. A recapitalisation of NCP Holdings led to a sale of 47.5% of our holdings for proceeds of £1.2m.

 

The decreases in the valuations in the period were partially offset by an FX gain of £0.6m, or 0.6p per share

 

Outlook

The biotechnology sector went into a tail spin back in September 2015 when the sector was trading at more than 30% above current levels due to political uncertainty surrounding drug pricing, sparked by Hillary Clinton's comments. The sector is yet to fully recover almost two years later.

 

After the setback, the NBI remained in a trading range throughout 2016, held back by the uncertainty of the upcoming US election.

 

Initially, despite the surprise Republican "clean sweep", investors remained cautious as Trump's comments surrounding drug pricing continued downward pressure on valuations. However, since his win, this has become a lesser area of concern and share prices have begun to recover, due to the long held assumption that "business friendly" Republicans are unlikely to vote for price controls or industry unfriendly ideas.

 

In practice, drug pricing growth is being 'controlled' to an extent already within the private sector through various mechanisms. Diseases which benefit from multiple treatment options offer insurance companies an opportunity to negotiate lower prices with the pharmaceutical and biotechnology companies supplying them. Despite the relatively recent political spotlight on drug pricing, this private sector negotiation on drug pricing is not a new phenomenon. By investing in companies focused on unmet medical needs and producing unique life changing drugs, investors can gain a degree of protection from such pressures.

 

Large pharmaceutical companies and more recently, large biotechnology companies, have seen their revenue growth rates reduce as current innovative therapies face greater competition and their R&D productivity in creating new drugs has decreased. Despite lower growth rates, their ability to generate cash from successful blockbuster drugs has continued, and many companies have significant cash resources. In addition, the new administration's polices look likely to increase cash holdings further. These policies include a potential lowering of corporate tax rates in the US and a one-off tax rate for 'repatriation of funds' which are locked overseas by some companies in order to avoid a 35% US corporate tax rate.

 

This combination of factors has led to increasing pressure on large cap companies in the sector to carry out M&A, and acquire companies with faster growing products to boost their revenue growth. Companies bought in M&A activity are often bought at 30-60% above the stock market values in the period immediately before acquisition, providing a strong source of returns for investors in the companies acquired. Frequently, these exiting investors seek to reinvest the proceeds in the biotech sector helping to further boost returns. The Investment Manager has taken steps to change the Company's holdings and reduce its exposure to the more established companies in favour of the faster growing mid-cap names which are ripe for acquisition.

 

We believe the sector remains good value at P/E of 13x 2017. However, it looks even more attractive on a relative basis when you consider the S&P 500's run and valuation of 18x 2017. We believe the fundamentals of the sector are intact, valuations are attractive and the concerns over Trump's administration are overdone, providing a good entry point for investors.

 

SV Life Sciences Managers LLP

Investment Manager

20 April 2017

 

Directors' Responsibility Statement

In respect of the Half Yearly Report for the six months ended 28 February 2017, we confirm that, to the best of our knowledge:

 

- the condensed set of Financial Statements contained within, which have been prepared in accordance with IAS 34, "Interim Financial Reporting", gives a true and fair view of the assets, liabilities, financial position and profit and loss of the Company as at 28 February 2017 as required by the UK Listing Authority's Disclosure Guidance and Transparency Rule 4.2.4R;

 

- the Chairman's Statement and Investment Manager's Review include a fair review, as required by Disclosure Guidance and Transparency Rule 4.2.7R, of important events that have occurred during the six months ended 28 February 2017 and their impact on the condensed set of Financial Statements, and a description of the principal risks and uncertainties for the remaining six months of the financial year; and

 

- the Chairman's Statement and Investment Manager's Review includes a fair review of the information concerning related party transactions as required by Disclosure Guidance and Transparency Rule 4.2.8R.

 

The Half Yearly Report has not been reviewed or audited by the Company's auditors.

 

The Half Yearly Report for the six months ended 28 February 2017 was approved by the Board and the above Responsibility Statement has been signed on its behalf by:

 

Alan Clifton

Chairman

20 April 2017

 

 

Statement of Comprehensive Income

for the six months ended 28 February 2017

 

 

 

(Unaudited)

(Unaudited)

(Audited)

 

 

For the six months ended

For the six months ended

For the year ended

 

 

28 February 2017

29 February 2016

31 August 2016

 

 

Company

Company

Company

 

 

Revenue

Capital

 

Revenue

Capital

 

Revenue

Capital

 

 

 

return

return

Total

return

return

Total

return

return

Total

 

Notes

£'000

£'000

£'000

£'000

£'000

£'000

£'000

£'000

£'000

Gains/(losses) on investments held at fair value through profit or loss

 

-

38,057

38,057

-

(39,027)

(39,027)

-

(1,725)

(1,725)

Exchange losses on currency balances

 

-

(539)

(539)

-

(1,438)

(1,438)

-

(2,333)

(2,333)

Income

2

203

-

203

334

-

334

676

-

676

Expenses

 

 

 

 

 

 

 

 

 

 

Management fees*

 

(274)

-

(274)

(999)

-

(999)

(1,894)

-

(1,894)

Performance fee

 

-

(1,901)

(1,901)

-

-

-

-

(575)

(575)

Administrative expenses

 

 

(568)

---------

-

---------

(568)

---------

(550)

---------

-

---------

(550)

---------

(1,047)

---------

-

---------

(1,047)

----------

Profit/(loss) before finance costs and tax

 

(639)

35,617

34,978

(1,215)

(40,465)

(41,680)

(2,265)

(4,633)

(6,898)

Finance costs

 

 

 

 

 

 

 

 

 

 

Interest payable

 

(84)

--------

-

---------

(84)

---------

(129)

----------

-

----------

(129)

---------

(212)

----------

-

----------

(212)

----------

Profit/(loss) on ordinary activities before tax

 

(723)

35,617

34,894

(1,344)

(40,465)

(41,809)

(2,477)

(4,633)

(7,110)

Taxation

 

(30)

--------

-

---------

(30)

---------

(52)

----------

-

----------

(52)

---------

(105)

---------

-

----------

(105)

----------

Profit/(loss) for the period attributable to owners of the Company

 

 

(753)

---------

35,617

---------

34,864

---------

(1,396)

----------

(40,465)

----------

(41,861)

---------

(2,582)

---------

(4,633)

----------

(7,215)

----------

Earnings/(loss) per Ordinary share

 

3

 

(2.01)p

======

94.85p

======

92.84p

======

(3.52)p

=======

(101.96) p

=======

(105.48) p

=======

(6.63)p

======

(11.89)p

======

(18.52)p

======

 

The total column of this statement represents the Company's Statement of Comprehensive Income prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the EU.

 

The Company does not have any other comprehensive income and hence the net (loss)/profit for the period, as disclosed above, is the same as the Company's total comprehensive income.

 

The revenue and capital columns are supplementary and are prepared under guidance published by the Association of Investment Companies (AIC).

 

*Following the investment into SV Fund VI on 3 October 2016, management fees are partially paid directly through the venture capital investment. Refer to note 6 related parties, for a reconciliation of the total amount paid.

 

The accompanying notes form part of these Financial Statements.

 

 

 

Balance Sheet

as at 28 February 2017

 

 

 

(Unaudited)

(Unaudited)

(Audited)

 

 

28 February 2017

29 February 2016

31 August 2016

 

 

Company

Company

Company

 

Notes

£'000

£'000

£'000

Non-current assets

 

 

 

 

Investments held at fair value through profit or loss

 

 

248,292

----------

187,498

-----------

221,788

------------

 

 

248,292

187,498

221,788

Current assets

 

 

 

 

Receivables

 

21,244

8,369

9,242

Cash and cash equivalents

 

141

----------

2,465

-----------

90

------------

 

 

21,385

----------

10,834

-----------

9,332

------------

Total assets

 

269,677

198,332

231,120

Current liabilities

 

 

 

 

Borrowings

 

(6,267)

-

(11,813)

Payables

 

(16,829)

-----------

(10,061)

------------

(2,656)

------------

 

 

(23,096)

-----------

(10,061)

------------

(14,469)

------------

Net assets

 

246,581

-----------

188,271

------------

216,651

------------

Equity attributable to equity holders

 

 

 

 

Called up share capital

 

10,336

10,723

10,409

Share premium account

 

18,805

18,805

18,805

Capital redemption reserve

 

31,481

31,094

31,408

Capital reserves

4

218,866

158,617

188,183

Revenue reserve

 

(32,907)

-----------

(30,968)

-----------

(32,154)

------------

Total equity

 

246,581

-----------

188,271

----------

216,651

------------

NAV per Ordinary share

5

 

656.71p

=======

481.66p

======

575.09p

========

 

The accompanying notes form part of these Financial Statements.

 

 

Statement of Changes in Equity

 

 

Called up

Share

Capital

 

 

 

Company

share

premium

redemption

Capital

Revenue

 

For the six months ended

capital

account

reserve

reserves

reserve

Total

28 February 2017 (Unaudited)

£'000

£'000

£'000

£'000

£'000

£'000

Balance at 1 September 2016

10,409

18,805

31,408

188,183

(32,154)

216,651

Total Comprehensive Income:

 

 

 

 

 

 

Profit/(loss) for the period

-

-

-

35,617

(753)

34,864

Transactions with owners, recorded directly to equity:

 

 

 

 

 

 

Shares bought back and held in treasury

-

-

-

(616)

-

(616)

Shares cancelled from treasury

(73)

-

73

-

-

-

Dividend paid in the period

-

---------

-

----------

-

----------

(4,318)

-----------

-

----------

(4,318)

----------

Balance at 28 February 2017

 

10,336

======

18,805

=======

31,481

=======

218,866

=======

(32,907)

=======

246,581

=======

 

Called up

Share

Capital

 

 

 

Company

share

premium

redemption

Capital

Revenue

 

For the six months ended

capital

account

reserve

reserves

reserve

Total

29 February 2016  (Unaudited)

£'000

£'000

£'000

£'000

£'000

£'000

Balance at 1 September 2015

11,116

18,805

30,701

204,440

(29,572)

235,490

Total Comprehensive Income:

 

 

 

 

 

 

Loss for the period

-

-

-

(40,465)

(1,396)

(41,861)

Transactions with owners, recorded directly to equity:

 

 

 

 

 

 

Shares bought back and held in treasury

-

-

-

(5,358)

-

(5,358)

Shares cancelled from treasury

 

(393)

---------

-

----------

393

-----------

-

----------

-

-----------

-

-----------

Balance at 29 February 2016

 

10,723

======

18,805

======

31,094

=======

158,617

======

(30,968)

=======

188,271

=======

 

Called up

Share

Capital

 

 

 

Company

share

premium

redemption

Capital

Revenue

 

For the year ended

capital

account

reserve

reserves

reserve

Total

31 August 2016         (Audited)

£'000

£'000

£'000

£'000

£'000

£'000

Balance at 1 September 2015

11,116

18,805

30,701

204,440

(29,572)

235,490

Total Comprehensive Income:

 

 

 

 

 

 

Loss for the year

-

-

-

(4,633)

(2,582)

(7,215)

Transactions with owners, recorded directly to equity:

 

 

 

 

 

 

Shares bought back and held in treasury

-

-

-

(11,624)

-

(11,624)

Shares cancelled from treasury

 

(707)

--------

-

---------

707

----------

-

----------

-

-----------

-

----------

Balance at 31 August 2016

10,409

=====

18,805

======

31,408

=======

188,183

======

(32,154)

=======

216,651

======

 

The accompanying notes form part of these Financial Statements.

 

 

 

Cash Flow Statement

 

 

(Unaudited)

(Unaudited)

(Audited)

 

For the six

For the six

For the

 

months ended

months ended

year ended

 

28 February 2017

29 February 2016

31 August 2016

 

Company

Company

Company

 

£'000

£'000

£'000

Cash flows from operating activities

 

 

 

Profit/(loss) before tax

34,894

(41,809)

(7,110)

Adjustments for:

 

 

 

(Increase)/decrease in investments

(26,504)

59,431

25,141

(Increase)/decrease in receivables

(12,002)

6,087

5,214

Increase/(decrease) in payables

14,173

5,734

(1,671)

Taxation

(30)

---------

(52)

----------

(105)

-----------

Net cash flows generated from operating activities

 

10,531

---------

29,391

----------

21,469

-----------

Cash flows from financing activities

 

 

 

Share repurchase costs

(616)

(5,358)

(11,624)

Dividend paid

(4,318)

----------

-

-----------

-

-----------

Net cash used in financing activities

 

(4,934)

----------

(5,358)

-----------

(11,624)

-----------

Net increase in cash and cash equivalents

5,597

24,033

9,845

Cash and cash equivalents at beginning of period

 

(11,723)

----------

(21,568)

----------

(21,568)

----------

Cash and cash equivalents at end of period

 

(6,126)

---------

2,465

---------

(11,723)

----------

 

The accompanying notes form part of these Financial Statements.

 

 

Notes to the Financial Statements

 

1. Accounting policies

The Financial Statements have been prepared on a going concern basis, in accordance with International Accounting Standard 34 "Interim Financial Reporting" and the accounting policies set out in the statutory accounts of the Company for the year ended 31 August 2016. Where presentational guidance set out in the Statement of Recommended Practice (the SORP) for investment trusts issued by the AIC in November 2014 and updated in January 2017 with consequential amendments, is consistent with the requirements of IFRS, the accounts have been prepared on a basis compliant with the recommendations of the SORP.

 

The financial information for each of the six month periods ended 28 February 2017 and 29 February 2016 comprises non-statutory accounts within the meaning of Sections 434 - 436 of the Companies Act 2006 (the Act). The financial information for the year ended 31 August 2016 has been extracted from published accounts that have been delivered to the Registrar of Companies and on which the report of the auditors was unqualified, did not draw attention to any matters by way of emphasis and did not contain a statement under Section 498(2) or (3) of the Act.

 

The Company has reviewed the guidance issued by the Financial Reporting Council (FRC) in order to determine whether the going concern basis should be used in preparing the Financial Statements for the six months ended 28 February 2017. The Directors have reviewed the likely operational costs and cashflows for the Company for the 12 months from the date of this Half Yearly Report, and are of the opinion that the Company has adequate resources to continue in operational existence for the foreseeable future. The Directors believe that it is appropriate to adopt the going concern basis in the preparation of the Financial Statements as there are no material uncertainties related to events or conditions that may cast significant doubt about the Company's ability to continue as a going concern.

 

The Company's principal risks and uncertainties remained unchanged to those described in the Annual Report for the year ended 31 August 2016. These include strategy/performance risks, investment-related risks, currency risks, operational risks and tax, legal and regulatory risks. These risks, and the way in which they are managed, are described in more detail under the heading "Principal risks and uncertainties" within the Strategic Report in the Company's Annual Report for the year ended 31 August 2016 as well as note 23 entitled "Financial Instruments and Risk Management".

 

2. Income

 

 

(Unaudited)

(Unaudited)

(Audited)

 

For the six

For the six

For the

 

months ended

months ended

year ended

 

28 February 2017

29 February 2016

31 August 2016

 

Company

Company

Company

 

£'000

£'000

£'000

Revenue:

 

 

 

Income from investments held at fair value through profit or loss:

 

 

 

Unfranked dividends

203

----------

334

----------

676

---------

 

203

======

334

======

676

======

 

3. Net earnings/(loss) per Ordinary share

 

 

(Unaudited)

(Unaudited)

(Audited)

 

For the six

For the six

For the

 

months ended

months ended

year ended

 

28 February 2017

29 February 2016

31 August 2016

 

Company

Company

Company

 

£'000

 

£'000

 

£'000

 

Net revenue loss

(753)

(1,396)

(2,582)

Net capital profit/(loss)

35,617

-----------

(40,465)

------------

(4,633)

-----------

 

34,864

=======

(41,861)

========

(7,215)

=======

Weighted average number of Ordinary shares in issue*

37,549,044

39,687,223

38,959,794

Revenue loss per Ordinary share

(2.01)p

(3.52)p

(6.63)p

Capital profit/(loss) per Ordinary share

 

94.85p

------------

(101.96)p

-------------

(11.89)p

------------

Total earnings/(loss) per Ordinary share

 

92.84p

=======

(105.48)p

========

(18.52)p

========

 

*Excluding those held in treasury.

 

 

4. Capital reserves

 

The capital reserve account comprises both realised gains on investments sold and unrealised gains and losses on investments held, which are analysed as follows:

 

 

(Unaudited)

(Unaudited)

(Audited)

 

For the six

For the six

For the

 

months ended

months ended

year ended

 

28 February 2017

29 February 2016

31 August 2016

 

Company

Company

Company

 

£'000

 

£'000

£'000

Capital reserve - on investments sold

200,176

159,580

168,447

Capital reserve - on investments held

18,690

-----------

(963)

----------

19,736

-----------

 

218,866

=======

158,617

=======

188,183

=======

 

5. Net asset value per Ordinary share

 

 

(Unaudited)

(Unaudited)

(Audited)

 

28 February 2017

29 February 2016

31 August 2016

 

Company

Company

Company

Net assets attributable to Ordinary Shareholders (£'000)

246,581

188,271

216,651

Ordinary shares in issue at end of period

37,547,663

39,087,663

37,672,663

NAV per Ordinary share

656.71p

481.66p

575.09p

 

6. Related party transactions

There have been no related party transactions that have materially affected the financial position or the performance of the Company during the six months ended to 28 February 2017.

 

(a) Transactions with the Investment Manager

Details of the management fee arrangement are given in the Directors' Report on page 19 of the Annual Report for the year ended 31 August 2016. Following the investment into the SV Fund VI venture capital fund on 3 October 2016, a portion of the management fee has been paid via fees due on this investment, with the remaining fees charged directly to the Company. The initial fee on the SV Fund VI investment was significantly higher than it will be on an ongoing basis to reflect the catch-up fees to equalise the position between the Company and earlier investors into the venture capital fund. The amounts paid can be seen in the table below and continue to total 0.9% of NAV. In the prior year, fees of £999,000 were paid in the six months ended 29 February 2016.

 

Fees paid to the Investment Manager

£

Venture Capital Fees paid through SV Fund VI investment

728,577

Management fee paid by the Company directly to the Investment Manager

274,054

-------------

Total

1,002,631

========

 

Due to the outperformance at 28 February 2017 vs the NBI benchmark plus 0.5% of 9.6%, a performance fee of £1,900,410 has been accrued. Performance is measured on an accrual basis and no amounts will be due or paid in respect of any outperformance until the release of the audited accounts for 31 August 2017.

 

(b) Related party transactions

The Directors of the Company are key management personnel. The total remuneration payable to Directors in respect of the six months ended 28 February 2017 was £79,500, of which £39,750 was outstanding at the period end.

 

7. Half Yearly Report

The Company's Half Yearly Report for the six months ended 28 February 2017 will be posted to Shareholders in April 2017. Copies of the Half Yearly Report will shortly be available from the Registered Office of the Company at 10 Harewood Avenue, London NW1 6AA and on the website, www.ibtplc.com, which is a website maintained by the Company's Investment Manager, SV Life Sciences Managers LLP. A copy of the Half Yearly Report for the six months ended 28 February 2017 has been submitted to the National Storage Mechanism of the UK Listing Authority and will shortly be available for inspection at: www.Hemscott.com/nsm.do. This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulations.

 

For further information, please contact:

 

Carl Harald Janson

Investment Manager

SV Life Sciences Managers LLP

Telephone: 020 7421 7070

 

Susan Gledhill

Company Secretary

BNP Paribas Secretarial Services Limited

Telephone: 020 7410 5971

 

21 APRIL 2017


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR BLGDSGUDBGRG

a d v e r t i s e m e n t